ENO2 and Nasal congestion: Similarly, the NSE + subgroup in all symptoms showed significant reduction between baseline and week 24; while only 2 symptoms, nasal congestion and anterior rhinorrhea, were significantly improved in the NSE-subgroup (Fig. 1 A5–D5).